Every Form 4 that Adagio Medical Holdings, Inc (ADGM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ADGM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADGM filings page.
Adagio Medical Holdings, Inc. director Keyvan Mirsaeedi-Farahani acquired 12,770 shares of common stock on September 27, 2024, through a pro rata distribution for no consideration. The shares were held directly, and his reported direct holdings following the transaction were 12,770 shares.
Adagio Medical Holdings, Inc. director Sean Salmon received a grant of 30,000 non-qualified stock options to buy common stock. The options have an exercise price of $0.7103 per share, expire on June 16, 2036, and will vest in 12 equal monthly installments over one year starting June 16, 2026.
Adagio Medical Holdings, Inc. reported that director Keyvan Mirsaeedi-Farahani received a grant of 30,000 non-qualified stock options on June 16, 2026. The options have an exercise price of $0.7103 per share and expire on June 16, 2036. They were granted under the company’s Non-Employee Director Compensation Policy and 2024 Equity Incentive Plan and will vest in 12 equal monthly installments over one year starting from the vesting commencement date of June 16, 2026. After this grant, the reporting person holds 30,000 options directly.
Adagio Medical Holdings, Inc. reported that director James L. Cox received a grant of a non-qualified stock option for 30,000 shares of common stock on June 16, 2026. The option has an exercise price of $0.7103 per share and expires on June 16, 2036. It vests in equal monthly installments over one year, with 1/12 of the shares vesting after each month of continuous service beginning on the vesting commencement date of June 16, 2026. Following this grant, Cox holds 30,000 option shares directly.
Adagio Medical Holdings, Inc. reported that director Sandra A. Gardiner received a grant of 30,000 non-qualified stock options on June 16, 2026 under the Non-Employee Director Compensation Policy and 2024 Equity Incentive Plan. The options have an exercise price of $0.7103 per share and expire on June 16, 2036. They vest in equal monthly installments over one year, with 1/12 of the underlying shares vesting at the end of each month of continuous service after the June 16, 2026 vesting commencement date, resulting in 30,000 options held directly after this grant.
Adagio Medical Holdings, Inc. director Orly Mishan received a grant of 100,000 non-qualified stock options on June 16, 2026 under the company’s Non-Employee Director Compensation Policy and 2024 Equity Incentive Plan. The options have an exercise price of $0.7103 per share and expire on June 16, 2036. They vest in equal monthly installments over one year, with 1/12 of the underlying shares vesting after each month of continuous service following the vesting commencement date of June 16, 2026.
Adagio Medical Holdings, Inc. reported that director Timothy P. Moran received a grant of 30,000 non-qualified stock options on 2026-06-16. The options have an exercise price of $0.7103 per share and expire on 2036-06-16.
The grant was made under the company’s Non-Employee Director Compensation Policy and 2024 Equity Incentive Plan. The option will vest in equal monthly installments over one year, with 1/12 of the underlying shares vesting at the conclusion of each month of continuous service after the vesting commencement date of 06/16/2026. Following this grant, Moran holds 30,000 derivative securities directly.
Adagio Medical Holdings, Inc. reported that Chief Financial Officer Deborah Kaster acquired 490,500 employee stock options on March 6, 2026. These options were granted under the company’s 2024 Equity Incentive Plan as a compensation award, not an open‑market share purchase.
According to the vesting terms, 25% of the option grant will vest on October 20, 2026, and the remaining options will vest in 36 equal monthly installments after that date. Following this grant, she holds 490,500 derivative securities directly.
Adagio Medical Holdings, Inc. director and Chief Executive Officer Todd Usen reported an acquisition of derivative securities through an option grant. He received 800,000 Employee Stock Options (Right to Buy) on March 6, 2026 as a grant or award, held directly.
According to the award terms, 25% of the options will vest on March 6, 2027, with the remaining options vesting in 36 equal monthly installments thereafter under the company’s 2024 Equity Incentive Plan.
Adagio Medical Holdings, Inc. reported an open market share purchase by its Chief Financial Officer, Deborah Kaster. On 12/16/2025, she bought 15,000 shares of common stock at a weighted average price of $1.1982 per share, and now beneficially owns 15,000 shares directly. The transaction was carried out in multiple trades, with prices ranging from $1.11 to $1.20 per share, and was reported as a purchase under the company’s insider reporting obligations.
Adagio Medical Holdings, Inc. reported that its Chief Executive Officer and director acquired 207,315 shares of its common stock in an open market transaction on 12/12/2025.
The shares were purchased at a weighted average price of $1.09 per share, with individual trade prices ranging from $0.9258 to $1.14101. After this transaction, the reporting person directly owned 207,315 shares of Adagio Medical common stock.
Adagio Medical Holdings, Inc. reported that a director acquired a non-qualified stock option to purchase 90,000 shares of common stock on 12/11/2025 at an exercise price of $0.8779 per share.
The option expires on 12/10/2035 and is held directly. The shares underlying the option will vest in 36 equal monthly installments starting January 11, 2026, subject to the director continuing to provide services on each vesting date.